optimal separation, sensitivity, and reproducibility during analytical method development.

2. Scope

This procedure applies to all HPLC, UPLC, and GC-based method development activities performed by the Analytical Method Development (AMD) department for drug substances, drug products, and related compounds.

3. Responsibilities

• Method Development Analyst: Conducts initial scouting, records trials, and optimizes parameters.
• Documentation Officer: Logs chromatographic condition screening trials in development records.
• QA Reviewer: Verifies condition selection rationale and compliance with applicable method development protocols.

4. Accountability

The Head – Analytical Method Development is accountable for the finalization, justification, and documentation of all chromatographic conditions used in validated and submitted analytical methods.

5. Procedure

5.1 Initial Literature Review

1. Search literature, pharmacopoeias, and regulatory filings for similar compounds or formulations.
2. Review prior in-house methods for related molecules or excipients.
3. Document reference methods and conditions explored (Annexure-1).

5.2 Column Selection

1. Select columns based on compound polarity, molecular weight, and ionization potential.
2. Begin with commonly used columns such as C18 (ODS), C8, phenyl-hexyl, or HILIC depending on analyte characteristics.
3. Document all columns evaluated and their performance metrics (e.g., retention time, resolution, peak symmetry).

5.3 Mobile Phase Composition

1. Test combinations of aqueous buffers (phosphate, acetate) and organic modifiers (acetonitrile, methanol).
2. Adjust pH to optimize analyte ionization and retention.
3. Use gradient elution for complex samples; isocratic for simpler ones.
4. Evaluate solvent strength, viscosity, and UV cutoff for compatibility.

5.4 Detection Settings

1. Scan analyte UV spectrum to determine optimal wavelength for detection (if UV is used).
2. In case of MS or ELSD, determine ionization parameters or nebulizer temperature, respectively.
3. Record baseline noise, sensitivity, and peak area reproducibility.

5.5 Flow Rate and Temperature

1. Begin with standard flow rate (1.0 mL/min for HPLC) and adjust based on backpressure, peak shape, and retention time.
2. Evaluate effect of column oven temperature on resolution and system pressure.
3. Use elevated temperatures for viscous mobile phases to improve peak shape.

5.6 System Suitability and Optimization

1. Inject system suitability solution after selecting tentative conditions.
2. Ensure parameters such as resolution ≥ 2.0, tailing ≤ 2.0, and RSD ≤ 2.0% for retention time and peak area.
3. Adjust column, mobile phase, or gradient program as necessary to meet these criteria.

5.7 Documentation

1. Record all trials in Method Development Worksheet (Annexure-2).
2. Summarize final selected conditions in Method Summary Sheet (Annexure-3).
3. Ensure traceability of changes and decisions with chromatograms and results.

6. Abbreviations

• HPLC: High Performance Liquid Chromatography
• UPLC: Ultra Performance Liquid Chromatography
• GC: Gas Chromatography
• RSD: Relative Standard Deviation
• UV: Ultraviolet

7. Documents

1. Annexure-1: Literature and Historical Method Review Log
2. Annexure-2: Method Development Worksheet
3. Annexure-3: Method Summary Sheet

8. References

• ICH Q2(R1) – Validation of Analytical Procedures
• USP <621> – Chromatography
• FDA Reviewer Guidance for Chromatographic Method Development

9. SOP Version

Version: 2.0

10. Approval Section

	Prepared By	Checked By	Approved By
Signature
Date
Name	Amit Khanna	Neha Kulkarni	Dr. Ramesh Patil
Designation	Method Developer	QA Officer	Head – AMD
Department	Analytical Method Development	Quality Assurance	Analytical Method Development

11. Annexures

Annexure-1: Literature and Historical Method Review Log

Source	Method Summary	Remarks
USP	C18, 0.1% Formic Acid in ACN	Suitable as initial trial
In-house	Previous method with methanol-water 60:40	Poor resolution for impurity

Annexure-2: Method Development Worksheet

Includes column selection, mobile phase screening, pH optimization, gradient programming, detection results, and chromatograms for each trial.

Annexure-3: Method Summary Sheet

Final selected conditions for validated method including column dimensions, flow rate, detection wavelength, injection volume, and mobile phase details.

Revision History:

Revision Date	Revision No.	Details	Reason	Approved By
01/06/2025	2.0	Expanded to include detection and temperature control procedures	Annual SOP Revision	Dr. Ramesh Patil
01/06/2022	1.0	Initial Issue	New SOP	QA Head